A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects (ZX-7101A-208)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06057103 |
|
Recruitment Status :
Recruiting
First Posted : September 28, 2023
Last Update Posted : September 28, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The primary object of this study is evaluating the effect of multiple oral oseltamivir phosphate capsules on the pharmacokinetic profile of the active metabolite ZX-7101 after a single oral administration of ZX-7101A tablet in healthy Chinese adult subjects.
The seongdary object is evaluating combined or uncombined multiple oral oseltamivir phosphate in healthy Chinese adult subjects.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Drug Interaction | Drug: ZX-7101A Drug: Oseltamivir Drug: ZX-7101A and Oseltamivir | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 18 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Crossover Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects -a Single-center, Open-labelled, Six-sequence, Three-cycle Crossover Design |
| Actual Study Start Date : | August 25, 2023 |
| Estimated Primary Completion Date : | April 29, 2024 |
| Estimated Study Completion Date : | April 29, 2024 |
| Arm | Intervention/treatment |
|---|---|
| ZX-7101A-1 |
Drug: ZX-7101A
ZX-7101A Tablets single dose tablet, 80 mg, Oral Drug: Oseltamivir Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral Drug: ZX-7101A and Oseltamivir ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral |
| ZX-7101A-2 |
Drug: ZX-7101A
ZX-7101A Tablets single dose tablet, 80 mg, Oral Drug: ZX-7101A and Oseltamivir ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral Drug: Oseltamivir Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral |
| Oseltamivir-1 |
Drug: Oseltamivir
Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral Drug: ZX-7101A ZX-7101A Tablets single dose tablet, 80 mg, Oral Drug: ZX-7101A and Oseltamivir ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral |
| Oseltamivir-2 |
Drug: Oseltamivir
Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral Drug: ZX-7101A and Oseltamivir ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral Drug: ZX-7101A ZX-7101A Tablets single dose tablet, 80 mg, Oral |
| Combined-1 |
Drug: ZX-7101A and Oseltamivir
ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral Drug: ZX-7101A ZX-7101A Tablets single dose tablet, 80 mg, Oral Drug: Oseltamivir Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral |
| Combined-2 |
Drug: ZX-7101A and Oseltamivir
ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral Drug: Oseltamivir Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral Drug: ZX-7101A ZX-7101A Tablets single dose tablet, 80 mg, Oral |
- PK parameters of active metabolite ZX-7101 in healthy Chinese adult subjects after a single oral ZX-7101A tablet combined with multiple oral oseltamivir phosphate capsules [ Time Frame: Day1,Day2,Day3,Day5,Day10,Day15,Day20;Conbined period Day1,Day2,Day3,Day6,Day10,Day15,Day20 ]Cmax
- PK parameters of active metabolite ZX-7101 in healthy Chinese adult subjects after a single oral ZX-7101A tablet combined with multiple oral oseltamivir phosphate capsules [ Time Frame: Day1,Day2,Day3,Day5,Day10,Day15,Day20;Conbined period Day1,Day2,Day3,Day6,Day10,Day15,Day20 ]AUC0-t
- PK parameters of active metabolite ZX-7101 in healthy Chinese adult subjects after a single oral ZX-7101A tablet combined with multiple oral oseltamivir phosphate capsules [ Time Frame: Day1,Day2,Day3,Day5,Day10,Day15,Day20;Conbined period Day1,Day2,Day3,Day6,Day10,Day15,Day20 ]AUC0-inf
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Healthy male or female subjects between the ages of 18 and 45 years (including the threshold value, based on the date of signing ICF).
Weight: Male weight ≥50 kg, female weight ≥45 kg, BMI between 19.0 and 28.0 kg/m2 (including cut-off value), BMI= weight (kg)/height 2 (m2).
The investigator judged the subjects to be in good overall health based on their medical history, physical examination, vital signs, 12-lead electrocardiogram, laboratory tests (routine blood work, urine work, blood biochemistry, coagulation function), viral serology, and chest X-ray results (normal or abnormal test results have no clinical significance).
Fertile female subjects or male subjects who voluntarily signed ICF should be no fertile, sperm/egg donation for 6 months (female) or 90 days (male) from the beginning to the last dose, and voluntary use highly effective contraception (including partner) (non-drug contraception is required during the trial).
Fully understand the trial content and possible adverse reactions, have the ability to communicate with researchers normally, while complying with study requirements, follow protocol procedures and restrictions, and be able to visit on time.
Exclusion Criteria:
Subjects with a prior or present history of clinically abnormal metabolic, liver, kidney, hematological, pulmonary, cardiovascular, gastrointestinal, urinary, endocrine, neurological, or psychiatric disease who were judged by the investigator to be unsuitable for participation in this study.
Subjects with digestive tract disease or any condition that may affect drug absorption, such as a history of liver and gallbladder disease, gastrointestinal disease, gastrointestinal surgery (except appendectomy) or a history of chronic pancreatitis, idiopathic acute pancreatitis, or habitual diarrhea.
Allergic constitutions (such as allergies to two or more drugs, foods, and pollen), or determined by the investigator, may be allergic to the investigational product or any component of the investigational product.
Acute respiratory infections within 2 weeks before screening; Or have a history of fungal infection.
For patients with abnormal vital signs (blood pressure, pulse rate, ear temperature) and clinically significant results, the abnormal values of each vital sign are:Body temperature (ear temperature) >37.5 ℃; Systolic blood pressure (recumbent) <90 mmHg or ≥140 mmHg; Diastolic blood pressure (lying) <50 mmHg or ≥90 mmHg; Pulse rate (lying position) <50 beats/min or >100 beats/min.
QTcF interval > 450ms or < 300 ms (Fridericia's correction), or QRS>120ms. Abnormal liver function: alanyl aminotransferase (ALT) or aspartate aminotransferase (AST) higher than the upper limit of normal or serum total bilirubin (TBIL) greater than 1.5 times the upper limit of normal, who judged clinical significance by investigators.
Subjects estimate glomerular filtration rate <90 mL/min/1.73 m2. Subjects virus serological test (hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, treponema pallidum specific antibody TPPA) positive results.
Subjects with a history of drug abuse (morphine, dimethylene dioxyamphetamine, methamphetamine, THC, ketamine, cocaine) or who screened positive for drug abuse.
Women who are pregnant or breastfeeding, or who test positive for blood pregnancy.
Subjects who have used any P-gp or CYP inducer or inhibitor within 30 days before screening, or any prescription or Chinese herbal medicine within 4 weeks before the start of the trial, or over-the-counter or health care products (including polyvalent cations and metal supplements, etc.) within 2 weeks before the start of the trial; It should have a longer time interval if the elimination half-life is longer-at least 5 elimination half-lives for the drug.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06057103
| Contact: Liu Dongyang, Doctor | 010-82265509 | liudongyang@vip.sina.com | |
| Contact: Wang Fangfang, Doctor | 010-68966677 | doctorfancy@126.com |
| China, Beijing | |
| Peking University Third Hospital | Recruiting |
| Beijing, Beijing, China | |
| Contact: Liu Dongyang, Doctor 010-82265509 liudongyang@vip.sina.com | |
| Responsible Party: | Nanjing Zenshine Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT06057103 |
| Other Study ID Numbers: |
ZX-7101A-208 |
| First Posted: | September 28, 2023 Key Record Dates |
| Last Update Posted: | September 28, 2023 |
| Last Verified: | September 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Oseltamivir Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |